Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase III Pipeline Programs

Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Programs 5,427
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 5,427 phase iii pharmaceutical pipeline programs from ClinicalTrials.gov. Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Top sponsors

Pipeline programs

Page 91 of 114

  1. Suzhou Sceneray® DBS System

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Opiate Addiction

    phase 3 other active

    1 trial

  2. Symbicort Turbuhaler

    AstraZeneca

    Asthma

    phase 3 small molecule completed

    1 trial

  3. Synthetic Conjugated estrogens, B

    Teva Pharma GmbH

    Menopause

    phase 3 small molecule completed

    1 trial

  4. Systematic oral health education

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Malignant Tumor of Head and/or Neck

    phase 3 other completed

    1 trial

  5. T89-08-ORESA

    Lacuna Pharma Pty Ltd

    Stable Angina Pectoris

    phase 3 small molecule active

    1 trial

  6. TAK-003

    Takeda

    Dengue Fever

    phase 3 mab completed

    1 trial

  7. TAK-019

    Takeda

    Coronavirus Disease (COVID-19)

    phase 3 mab completed

    1 trial

  8. TAK-079-3001

    Takeda

    IgAN is Primary Immunoglobulin A Nephropathy (IgAN) (also known as Berger's disease)

    phase 3 small molecule active

    1 trial

  9. TAK-279

    Takeda

    Plaque Psoriasis

    phase 3 small molecule active

    3 trials

  10. TAK-279

    Takeda

    Generalized Pustular Psoriasis

    phase 3 small molecule active

    1 trial

  11. TAK-279-3001

    Takeda

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  12. TAK-279-3002

    Takeda

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  13. TAK-279-PsA-3001

    Takeda

    Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  14. TAK-279-PsA-3002

    Takeda

    Active Psoriatic Arthritis Stratified by Prior Biologic Use

    phase 3 small molecule active

    1 trial

  15. TAK-279-PsA-3003

    Takeda

    Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  16. TAK-279-PsO-3004

    Takeda

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  17. TAK-330

    Takeda

    Coagulation Disorder

    phase 3 small molecule active

    1 trial

  18. TAK-339-3001

    Takeda

    Primary infection prophylaxis for secondary immunodeficiency (SID) in patients with multiple myeloma (MM) receiving B cell maturation antigen (BCMA)-directed bispecific (BsAb) therapy

    phase 3 small molecule active

    1 trial

  19. TAK-438

    Takeda

    Non-erosive Gastroesophageal Reflux Disease

    phase 3 small molecule completed

    1 trial

  20. TAK-438

    Takeda

    Gastric Ulcer

    phase 3 small molecule completed

    4 trials

  21. TAK-438

    Takeda

    Gastric Ulcers

    phase 3 small molecule completed

    4 trials

  22. TAK-438

    Takeda

    H. Pylori Infection

    phase 3 small molecule completed

    1 trial

  23. TAK-438

    Takeda

    Erosive Esophagitis

    phase 3 small molecule completed

    4 trials

  24. TAK-438

    Takeda

    Duodenal Ulcer

    phase 3 small molecule completed

    2 trials

  25. TAK-536

    Takeda

    Hypertension

    phase 3 small molecule completed

    1 trial

  26. TAK-536CCB

    Takeda

    Grade I or II Essential Hypertension

    phase 3 small molecule completed

    1 trial

  27. TAK-536TCH tablet

    Takeda

    Essential Hypertension

    phase 3 small molecule completed

    1 trial

  28. TAK-559

    Takeda

    Diabetes Mellitus

    phase 3 small molecule terminated

    3 trials

  29. TAK-559 and glyburide

    Takeda

    Diabetes Mellitus

    phase 3 small molecule terminated

    1 trial

  30. TAK-559 and insulin

    Takeda

    Diabetes Mellitus

    phase 3 small molecule terminated

    1 trial

  31. TAK-559 and metformin

    Takeda

    Diabetes Mellitus

    phase 3 small molecule terminated

    1 trial

  32. TAK-577-3001

    Takeda

    severe von Willebrand Disease

    phase 3 small molecule active

    1 trial

  33. TAK-583

    Takeda

    Neuralgia, Postherpetic

    phase 3 small molecule completed

    1 trial

  34. TAK-620-2004

    Takeda

    Cytomegalovirus (CMV) infection in children and adolescents who have received a hematopoietic stem cell transplant (HSCT) or a solid organ transplant (SOT)

    phase 3 small molecule active

    1 trial

  35. TAK-625

    Takeda

    Progressive Familial Intrahepatic Cholestasis (PFIC)

    phase 3 small molecule completed

    1 trial

  36. TAK-625

    Takeda

    Alagille Syndrome (ALGS)

    phase 3 small molecule completed

    1 trial

  37. TAK-667

    Takeda

    Hereditary Angioedema

    phase 3 small molecule completed

    1 trial

  38. TAK-672

    Takeda

    Acquired Hemophilia A

    phase 3 mab completed

    1 trial

  39. TAK-743 300 mg

    Takeda

    Hereditary Angioedema

    phase 3 small molecule completed

    1 trial

  40. TAK-755

    Takeda

    Thrombotic Thrombocytopenic Purpura (TTP)

    phase 3 mab active

    3 trials

  41. TAK-755-3002

    Baxalta Innovations GmbH

    Congenital Thrombotic thrombocytopenic purpura (cTTP)

    phase 3 small molecule active

    1 trial

  42. TAK-771

    Takeda

    Primary Immunodeficiency Diseases (PID)

    phase 3 small molecule completed

    2 trials

  43. TAK-771

    Takeda

    Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

    phase 3 small molecule active

    1 trial

  44. TAK-788

    Takeda

    Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  45. TAK-816

    Takeda

    Healthy Volunteers

    phase 3 mab completed

    1 trial

  46. TAK-816+ DPT-TAKEDA

    Takeda

    Immunization

    phase 3 mab completed

    1 trial

  47. TAK-861

    Takeda

    Narcolepsy Type 1

    phase 3 small molecule active

    4 trials

  48. TAK-861

    Takeda

    Narcolepsy Type 1 (NT1)

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many Phase III pipeline programs are in the directory?

5,427 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.